11 - 2024 | AI-Mind

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 964220. This website reflects only the author’s view and the Commission is not responsible for any use that may be made of the information it contains.

Positive EMA decision on lecanemab highlights importance of AI-Mind’s work

Positive European Medicines Agency decision on lecanemab highlights importance of AI-Mind’s work On 14 November 2024, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended […]

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 964220.

For any inquiries you can also send an email to [email protected]

©accelopment Schweiz AG and Oslo University Hospital 2025 · [email protected] · ISO 9001 certified · Read our Cookie Policy and Privacy Policy

Day: 18 November 2024

Positive EMA decision on lecanemab highlights importance of AI-Mind’s work